Valeria Caceres

8th International Consensus Guidelines for the management of advanced breast cancer (ABC8 Guidelines)

Fátima Cardoso, Joana Mourato Ribeiro, Eva Schumacher-Wulf, Sandra M. Swain et autres

TroFuse-022/ENGOT-ov84/GOG-3103 part 2: A phase 3 study of maintenance therapy with sacituzumab tirumotecan ± bevacizumab vs standard of care following second-line platinum-based doublet chemotherapy for platinum-sensitive recurrent ovarian cancer.

Antonio Gonzalez Martin, Thomas J. Herzog, Kosei Hasegawa, Coriolan Lebreton et autres

TPS5636 Background: There is an unmet clinical need for novel therapies for patients with platinum-sensitive recurrent ovarian cancer (PSROC). Trophoblast cell-surface antigen 2 (TROP2) is highly expressed in multiple tumor types, including ovarian cancer. Sacituzumab tirumotecan (sac-TMT) is a TROP2-directed antibody-drug conjugate …

es, jp, fr, us, ca, kr, cz, gb, ar, dk, be, il (code pays fourni par la source)

Development of a multivariable prognostic model for pathological response using anatomical and pathological variables in early triple-negative breast cancer treated with neoadjuvant chemo-immunotherapy: Initial results.

Dana Narvaez, Adrian Agustin Nervo, Jorge Carlos Nadal, Giuliana Colucci et autres

612 Background: The combination of chemotherapy and immune checkpoint inhibitors is the standard of care for most patients with early triple negative breast cancer (eTNBC). Higher residual cancer burden (RCB) after receiving neoadjuvant chemo-immunotherapy (NCI) is associated with worse outcomes; however, reliable …

ar (code pays fourni par la source)

Physician treatment decisions for hormone receptor-positive, HER2-negative early breast cancer in young patients: a Latin American survey

Dana P. Narvaez, Federico Waisberg, Cynthia Mayte Villarreal-Garza, Sergio Gabriel Rivero et autres

Background: The management of hormone receptor-positive (HR+), HER2-negative early breast cancer in young women presents unique challenges due to the absence of standardized guidelines and variability in clinical decision-making. In Latin America, these challenges are compounded by disparities in healthcare systems and …

ar, mx, pe, cl, us, bo, pa, hn, co (code pays fourni par la source)

Abstract P4-11-15: Variability in physician treatment decisions for HR+ / HER 2 negative Early Breast Cancer in young patients: a Latin-American survey

Dana P. Narvaez, Federico Waisberg, Victoria Costanzo, Danilo Aguirre et autres

Abstract Introduction: Breast cancer in young people (age ≤ 40), represents 5% of all breast cancer cases. Population outcomes for this group are often derived from subgroup analyses of randomized or retrospective trials. Limited data about physicians' knowledge, attitudes and practices as …

Abstract PO3-08-06: Challenges in Implementing Genetic Counseling and Genetic Testing for Breast Cancer: Insights from the First 1000 Families Assessed in a Public University Hospital in Argentina

Dolores Mansilla, Diana Bequelman, Jorgelina Cavallero, Hernan Ursino et autres

Abstract Introduction: Integrating genetic testing into breast cancer patients care is crucial for personalized treatment recommendations, risk reduction strategies, and family members evaluation. However, Argentina faces several concerns in implementing these services. Objective: This study aims to explore the challenges encountered in …

it (code pays fourni par la source)

Abstract PO4-16-07: Cyclin-dependent kinase inhibitor plus endocrine therapy in HR+/HER2- invasive breast cancer with bone marrow and pancytopenia: a new standard of care? Collaborative multicentric Argentinean real-world study (SUMA-02)

Alexis Ostinelli, Pablo Mandó, Carolina Almada, Melina Winocur et autres

Abstract Introduction Bone marrow involvement is a rare occurrence in patients with advanced breast cancer (ABC), and the prognosis in this context is generally poor. Prompt initiation of treatment to improve the patient's hematological status is crucial. However, this condition is often …

ar, es (code pays fourni par la source)

SP6 antibody is an accurate method to validate Ki67 proliferation index

Gabriela Acosta Haab, Sandra Sarancone, Isabel Frahm, Valeria Caceres

ar (code pays fourni par la source)

Allo‐Anti‐C in a Patient Who Had Previously Made an Autoantibody Mimicking Anti‐C

Joachim E. Weber, Valeria Caceres, BEVERLY G. PAVONE, P. D. Issitt

A patient, previously studied by us, who had produced a benign autoantibody with a specificity that mimicked anti-C, has now produced allo-anti-C that is not of the mimicking type. She is no longer producing any serologically demonstrable autoantibody. It is highly probable …

us (code pays fourni par la source)